Search Results
EHA 2013: Adding obinutuzumab or rituximab to chlorambucil improves chronic lymphocytic leukaemia
Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
Obinutuzumab increases survival in CLL patients with comorbidities
Dr. Valentin Goede on Obinutuzumab Versus Rituximab in CLL
Emerging anti-CD20 monoclonal antibodies as first-line therapy in elderly CLL
iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil
5-year update of ELEVATE CLL TN
CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil
How to treat a previously untreated CLL patient
Dr. Goede on the Results from the Phase III CLL11 Trial
CLL11 trial: tackling tough-to-treat CLL patients with co-morbidities
Time-limited vs continuous therapy in CLL treatment
